BR112014029300A2 - genes nano46 e métodos para prever resultado de câncer de mama - Google Patents

genes nano46 e métodos para prever resultado de câncer de mama

Info

Publication number
BR112014029300A2
BR112014029300A2 BR112014029300A BR112014029300A BR112014029300A2 BR 112014029300 A2 BR112014029300 A2 BR 112014029300A2 BR 112014029300 A BR112014029300 A BR 112014029300A BR 112014029300 A BR112014029300 A BR 112014029300A BR 112014029300 A2 BR112014029300 A2 BR 112014029300A2
Authority
BR
Brazil
Prior art keywords
methods
breast cancer
outcome
individual
genes
Prior art date
Application number
BR112014029300A
Other languages
English (en)
Inventor
M Perou Charles
J Storhoff James
S Parker Joel
J Ellis Matthew
S Bernard Philip
M Ferree Sean
O Nielsen Torsten
Original Assignee
British Columbia Cancer Agency Branch
Nanostring Technologies Inc
Univ North Carolina Chapel Hill
Univ Utah Res Found
Univ Washington
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by British Columbia Cancer Agency Branch, Nanostring Technologies Inc, Univ North Carolina Chapel Hill, Univ Utah Res Found, Univ Washington filed Critical British Columbia Cancer Agency Branch
Publication of BR112014029300A2 publication Critical patent/BR112014029300A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/118—Prognosis of disease development
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers

Landscapes

  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Pathology (AREA)
  • Analytical Chemistry (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • Hospice & Palliative Care (AREA)
  • Biophysics (AREA)
  • Oncology (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)

Abstract

resumo “genes nano46 e métodos para prever resultado de câncer de mama” a presente invenção fornece métodos para classificação e para avaliação do prognóstico de um indivíduo que possui câncer de mama. os métodos incluem a previsão do subtipo de câncer de mama utilizando um algoritmo supervisionado trei-nado para estratificar indivíduos com base do subtipo de câncer de mama intrínseco. o modelo de previsão se baseia no perfil de expressão gênica dos genes intrínsecos listados na tabela 1. são adicionalmente fornecidas composições e métodos para a previsão do resultado ou da resposta à terapia de um indivíduo diagnosticado com ou suspeito de ter câncer de mama. estes métodos são úteis para guiar ou para determinar opções de tratamento para um indivíduo afligido com câncer de mama. os métodos da invenção incluem ainda meios para a avaliação de perfis de expressão gênica, incluindo microarranjos e ensaios quantitativos de reação em cadeia da polimerase, bem como kits que compreendem reagentes para a prática dos métodos da invenção.
BR112014029300A 2012-05-22 2013-05-22 genes nano46 e métodos para prever resultado de câncer de mama BR112014029300A2 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261650209P 2012-05-22 2012-05-22
US201361753673P 2013-01-17 2013-01-17
PCT/US2013/042157 WO2013177245A2 (en) 2012-05-22 2013-05-22 Nano46 genes and methods to predict breast cancer outcome

Publications (1)

Publication Number Publication Date
BR112014029300A2 true BR112014029300A2 (pt) 2017-07-25

Family

ID=49624503

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112014029300A BR112014029300A2 (pt) 2012-05-22 2013-05-22 genes nano46 e métodos para prever resultado de câncer de mama

Country Status (12)

Country Link
US (3) US20130337444A1 (pt)
EP (1) EP2852689B1 (pt)
JP (1) JP6325530B2 (pt)
CN (2) CN104704128A (pt)
AU (1) AU2013266419B2 (pt)
BR (1) BR112014029300A2 (pt)
CA (1) CA2874492C (pt)
ES (1) ES2763931T3 (pt)
IL (1) IL235795B (pt)
IN (1) IN2014MN02418A (pt)
MX (1) MX369628B (pt)
WO (1) WO2013177245A2 (pt)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2664679B1 (en) 2008-05-30 2017-11-08 The University of North Carolina At Chapel Hill Gene expression profiles to predict breast cancer outcomes
WO2012125828A2 (en) 2011-03-15 2012-09-20 The University Of North Carolina At Chapell Hill Methods of treating breast cancer with anthracycline therapy
GB201106254D0 (en) 2011-04-13 2011-05-25 Frisen Jonas Method and product
AU2012345789B2 (en) 2011-11-30 2018-02-15 British Columbia Cancer Agency Branch Methods of treating breast cancer with taxane therapy
EP2909337B1 (en) 2012-10-17 2019-01-09 Spatial Transcriptomics AB Methods and product for optimising localised or spatial detection of gene expression in a tissue sample
US20160115551A1 (en) * 2013-05-13 2016-04-28 Nanostring Technologies, Inc. Methods to predict risk of recurrence in node-positive early breast cancer
DK3013984T3 (da) 2013-06-25 2023-06-06 Prognosys Biosciences Inc Metode til bestemmelse af spatiale mønstre i biologiske targets i en prøve
JP2016537010A (ja) * 2013-09-09 2016-12-01 ブリティッシュ コロンビア キャンサー エージェンシー ブランチ 予後を予測するための方法及びキット、並びに、放射線照射療法を用いた乳癌の治療方法及びキット
KR20220100098A (ko) 2014-11-21 2022-07-14 나노스트링 테크놀로지스, 인크. 무효소 및 무증폭 시퀀싱
WO2016085841A1 (en) * 2014-11-24 2016-06-02 Nanostring Technologies, Inc. Methods and apparatuses for gene purification and imaging
AU2015359479A1 (en) * 2014-12-09 2017-06-15 King's College London Breast cancer treatment with taxane therapy
ES2972835T3 (es) 2015-04-10 2024-06-17 10X Genomics Sweden Ab Análisis multiplex de especímenes biológicos de ácidos nucleicos espacialmente distinguidos
WO2017014694A1 (en) * 2015-07-23 2017-01-26 National University Of Singapore Wbp2 as a co-prognostic factor with her2 for stratification of patients for treatment
AU2017268257B2 (en) 2016-05-16 2023-09-07 Bruker Spatial Biology, Inc. Methods for detecting target nucleic acids in a sample
US11352667B2 (en) 2016-06-21 2022-06-07 10X Genomics, Inc. Nucleic acid sequencing
WO2018074865A2 (ko) * 2016-10-21 2018-04-26 서울대학교병원 유방암 예후 예측용 조성물 및 방법
CA3043489A1 (en) 2016-11-21 2018-05-24 Nanostring Technologies, Inc. Chemical compositions and methods of using same
KR101950717B1 (ko) * 2016-11-23 2019-02-21 주식회사 젠큐릭스 유방암 환자의 화학치료 유용성 예측 방법
WO2018144782A1 (en) * 2017-02-01 2018-08-09 The Translational Genomics Research Institute Methods of detecting somatic and germline variants in impure tumors
EP3668998A1 (en) 2017-10-06 2020-06-24 Cartana AB Rna templated ligation
KR102071491B1 (ko) * 2017-11-10 2020-01-30 주식회사 디시젠 차세대 염기서열분석을 이용한 기계학습 기반 유방암 예후 예측 방법 및 예측 시스템
EP3794146A1 (en) 2018-05-14 2021-03-24 Nanostring Technologies, Inc. Chemical compositions and methods of using same
CN113302313A (zh) * 2018-11-05 2021-08-24 拜恩科技诊断有限责任公司 乳腺癌的预测方法
CA3139791A1 (en) 2019-05-31 2020-12-03 10X Genomics, Inc. Method of detecting target nucleic acid molecules
JP7352937B2 (ja) * 2019-07-19 2023-09-29 公立大学法人福島県立医科大学 乳癌のサブタイプを鑑別又は分類するための鑑別マーカー遺伝子セット、方法およびキット
EP3945136A1 (en) * 2020-07-28 2022-02-02 Hospital Clínic de Barcelona In vitro method for the prognosis of patients suffering from her2-positive breast cancer
US12060603B2 (en) 2021-01-19 2024-08-13 10X Genomics, Inc. Methods for internally controlled in situ assays using padlock probes
EP4453259A1 (en) * 2021-12-20 2024-10-30 Reveal Genomics S.L. Development and validation of an in vitro method for the prognosis of patients suffering from her2-positive breast cancer
CN117965734B (zh) * 2024-02-02 2024-09-24 奥明星程(杭州)生物科技有限公司 一种用于检测硬纤维瘤的基因标志物、试剂盒、检测方法及应用

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5800992A (en) 1989-06-07 1998-09-01 Fodor; Stephen P.A. Method of detecting nucleic acids
US6040138A (en) 1995-09-15 2000-03-21 Affymetrix, Inc. Expression monitoring by hybridization to high density oligonucleotide arrays
EP0604552B1 (en) 1991-09-18 1997-02-12 Affymax Technologies N.V. Method of synthesizing diverse collections of oligomers
US5677195A (en) 1991-11-22 1997-10-14 Affymax Technologies N.V. Combinatorial strategies for polymer synthesis
US5384261A (en) 1991-11-22 1995-01-24 Affymax Technologies N.V. Very large scale immobilized polymer synthesis using mechanically directed flow paths
US5856174A (en) 1995-06-29 1999-01-05 Affymetrix, Inc. Integrated nucleic acid diagnostic device
EP0880598A4 (en) 1996-01-23 2005-02-23 Affymetrix Inc RAPID EVALUATION OF NUCLEIC ACID ABUNDANCE DIFFERENCE, WITH A HIGH-DENSITY OLIGONUCLEOTIDE SYSTEM
JP2001521753A (ja) 1997-10-31 2001-11-13 アフィメトリックス インコーポレイテッド 成人臓器及び胎児臓器中の発現プロフィール
US6020135A (en) 1998-03-27 2000-02-01 Affymetrix, Inc. P53-regulated genes
US6750015B2 (en) * 2000-06-28 2004-06-15 Kathryn B. Horwitz Progesterone receptor-regulated gene expression and methods related thereto
US20020168639A1 (en) * 2000-09-22 2002-11-14 Muraca Patrick J. Profile array substrates
US7056674B2 (en) * 2003-06-24 2006-06-06 Genomic Health, Inc. Prediction of likelihood of cancer recurrence
EP2469439A2 (en) * 2003-09-29 2012-06-27 Pathwork Diagnostics, Inc. Systems and methods for detecting biological features
CA2574447A1 (en) 2004-07-15 2006-01-26 University Of Utah Research Foundation Housekeeping genes and methods for identifying the same
CN101061480A (zh) * 2004-09-22 2007-10-24 三路影像公司 用来分析和优化用于癌症诊断的标记候选物的方法和计算机程序产品
US20090299640A1 (en) 2005-11-23 2009-12-03 University Of Utah Research Foundation Methods and Compositions Involving Intrinsic Genes
AU2006330834B2 (en) 2005-12-23 2013-09-12 Bruker Spatial Biology, Inc. Compositions comprising oriented, immobilized macromolecules and methods for their preparation
EP1963531B1 (en) 2005-12-23 2011-09-21 Nanostring Technologies, Inc. Nanoreporters and methods of manufacturing and use thereof
WO2008124847A2 (en) 2007-04-10 2008-10-16 Nanostring Technologies, Inc. Methods and computer systems for identifying target-specific sequences for use in nanoreporters
WO2008150512A2 (en) * 2007-06-04 2008-12-11 University Of Louisville Research Foundation, Inc. Methods for identifying an increased likelihood of recurrence of breast cancer
ES2618353T3 (es) * 2007-09-06 2017-06-21 Biotheranostics, Inc. Clasificación de tumores y pronóstico del cáncer de mama
EP2664679B1 (en) * 2008-05-30 2017-11-08 The University of North Carolina At Chapel Hill Gene expression profiles to predict breast cancer outcomes
JP5836803B2 (ja) 2008-08-14 2015-12-24 ナノストリング テクノロジーズ， インコーポレイテッド 安定したナノレポーター
UA110790C2 (uk) * 2010-03-31 2016-02-25 Сівідон Діагностікс Гмбх Спосіб передбачування рецидиву раку молочної залози при ендокринному лікуванні

Also Published As

Publication number Publication date
CN104704128A (zh) 2015-06-10
AU2013266419B2 (en) 2018-09-27
EP2852689B1 (en) 2019-12-11
IL235795B (en) 2020-02-27
AU2013266419A1 (en) 2014-12-11
IL235795A0 (en) 2015-01-29
US20130337444A1 (en) 2013-12-19
EP2852689A4 (en) 2016-05-11
IN2014MN02418A (pt) 2015-08-14
WO2013177245A3 (en) 2015-01-29
US20230272476A1 (en) 2023-08-31
ES2763931T3 (es) 2020-06-01
CA2874492A1 (en) 2013-11-28
JP2015518724A (ja) 2015-07-06
CN111500718A (zh) 2020-08-07
JP6325530B2 (ja) 2018-05-16
CA2874492C (en) 2021-10-19
EP2852689A2 (en) 2015-04-01
WO2013177245A2 (en) 2013-11-28
US20200332368A1 (en) 2020-10-22
MX2014014275A (es) 2015-07-06
MX369628B (es) 2019-11-14

Similar Documents

Publication Publication Date Title
BR112014029300A2 (pt) genes nano46 e métodos para prever resultado de câncer de mama
CY1114993T1 (el) Προφιλ εκφρασης γονιδιου για να προβλεπονται εκβασεις καρκινου μαστου
Zhang et al. Whole‐genome microRNA expression profiling identifies a 5‐microRNA signature as a prognostic biomarker in Chinese patients with primary glioblastoma multiforme
Khan et al. Four genes predict high risk of progression from smoldering to symptomatic multiple myeloma (SWOG S0120)
BR112015023120A2 (pt) método para identificar um indivíduo com uma doença ou disfunção, método para prever a responsividade de um indivíduo com uma doença ou disfunção, método para determinar a probabilidade de que um indivíduo com uma doença ou disfunção exibirá benefício do tratamento, método para selecionar uma terapia, usos de um antagonista de ligação do eixo pd-l1, ensaio para identificar um indivíduo com uma doença, kit de diagnóstico, método para avaliar uma resposta ao tratamento e método para monitorar a resposta de um indivíduo tratado
MX2019007814A (es) Algoritmo de perfil de expresion genica y prueba para determinar la prognosis de cancer de prostata.
EA201390762A1 (ru) Новые биомаркеры для предсказания исхода противораковой иммунотерапии
BR112014007214A2 (pt) predição de evento de risco cardiovascular e utilização do mesmo
GB2503148A (en) Biomarker panels diagnostic methods and test kits for ovarian cancer
WO2015087088A3 (en) Prostate cancer classification
AR099856A1 (es) Métodos para diagnosticar y tratar la enfermedad de intestino inflamado
Stamatopoulos et al. A molecular score by quantitative PCR as a new prognostic tool at diagnosis for chronic lymphocytic leukemia patients
BR112022004094A2 (pt) Biomarcadores para predizer atividade de doença de esclerose múltipla
Davey et al. Clinicopathological correlates, oncological impact, and validation of Oncotype DX™ in a European Tertiary Referral Centre
Lin et al. Four-miRNA signature as a prognostic tool for lung adenocarcinoma
BRPI0608429A2 (pt) método e kit para prognóstico ou avaliação da eficácia do tratamento de um tumor sólido em um paciente de interesse; e método para a identificação de marcadores que sejam prognósticos de um tumor sólido
Gee et al. MicroRNA-related DNA repair/cell-cycle genes independently associated with relapse after radiation therapy for early breast cancer
Collins et al. Clinical decision aids in colon cancer: a comparison of two predictive nomograms
WO2020123880A3 (en) Genomic rearrangements associated with prostate cancer and methods of using the same
BRPI0507392A (pt) método e kit para determinar a possibilidade de metástase de cáncer em um indivìduo
Eapen Relapsed acute lymphoblastic leukemia: Is it crucial to achieve molecular remission prior to transplant?
Lin et al. A seven-immune-genes risk model predicts the survival and suitable treatments for patients with skin cutaneous melanoma
JP7430655B2 (ja) 高悪性度漿液性卵巣癌の治療的治癒についてのｍｉＲＮＡの予測的及び予後的使用
Fustero-Torre et al. Beyondcell: targeting cancer therapeutic heterogeneity in single-cell RNA-seq
Liu et al. Molecular Subtyping of Skin Cutaneous Melanoma Based on Inflammatory Response

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B06I Publication of requirement cancelled [chapter 6.9 patent gazette]

Free format text: ANULADA A PUBLICACAO CODIGO 6.6.1 NA RPI NO 2462 DE 13/03/2018 POR TER SIDO INDEVIDA.

B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B07G Grant request does not fulfill article 229-c lpi (prior consent of anvisa) [chapter 7.7 patent gazette]
B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B350 Update of information on the portal [chapter 15.35 patent gazette]
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]

Free format text: MANTIDO O INDEFERIMENTO UMA VEZ QUE NAO FOI APRESENTADO RECURSO DENTRO DO PRAZO LEGAL.MANTIDO O INDEFERIMENTO UMA VEZ QUE NAO FOI APRESENTADO RECURSO DENTRO DO PRAZO LEGAL.